CXCL8 and neoplasm: Finally, to avoid ineffective second-line immunotherapy in melanoma patients with a high level of IL-8, it might be worth investigating whether immune checkpoint inhibitors can be combined with the agent(s) targeting IL-8 or its receptors to decrease immunosuppression within the tumor microenvironment.